Can-Fite(CANF) - 2023 Q4 - Annual Report

Can-Fite Reports 2023 Financial Results and Clinical Update RAMAT GAN, Israel, March 28, 2024 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023. Namodenoson Drug Candidate: 2. Can-Fite Broadens its Strong Intellectual Property (IP) for NASH (MASH): Received Patent ...